VIRX
Income statement / Annual
Last year (2023), Viracta Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Viracta Therapeutics, Inc.'s net income was -$51.06 M.
See Viracta Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$120.00 K |
$2.07 M |
$237.00 K |
$669.00 K |
$2.54 M |
$3.06 M |
$5.73 M |
| Cost of Revenue |
$492.00 K
|
$210.00 K
|
$178.00 K
|
$32.00 K
|
$0.00
|
-$902.75 K
|
$9.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$492.00 K
|
-$210.00 K
|
-$178.00 K
|
$88.00 K
|
$2.07 M
|
$1.14 M
|
$660.00 K
|
$2.54 M
|
$3.06 M
|
$5.73 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0.73
|
1
|
4.81
|
0.99
|
1
|
1
|
1
|
| Research and Development Expenses |
$33.37 M
|
$26.26 M
|
$23.86 M
|
$13.47 M
|
$15.41 M
|
$14.62 M
|
$21.54 M
|
$22.88 M
|
$23.70 M
|
$27.67 M
|
| General & Administrative Expenses |
$17.32 M
|
$24.33 M
|
$15.44 M
|
$5.35 M
|
$3.19 M
|
$2.14 M
|
$13.55 M
|
$16.12 M
|
$18.66 M
|
$23.11 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.95 M
|
$9.18 M
|
-$9.00 K
|
-$11.00 K
|
-$27.00 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.32 M
|
$24.33 M
|
$15.44 M
|
$5.35 M
|
$9.95 M
|
$11.32 M
|
$13.54 M
|
$16.10 M
|
$18.64 M
|
$23.11 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$13.50 M
|
-$34.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$50.69 M
|
$50.59 M
|
$25.80 M
|
$18.82 M
|
$25.36 M
|
$25.94 M
|
$35.08 M
|
$38.99 M
|
$42.34 M
|
$50.78 M
|
| Cost And Expenses |
$50.69 M
|
$50.59 M
|
$25.80 M
|
$18.82 M
|
$25.36 M
|
$25.95 M
|
$35.09 M
|
$39.00 M
|
$42.36 M
|
$50.78 M
|
| Interest Income |
$3.35 M
|
$1.17 M
|
$38.00 K
|
$48.00 K
|
$472.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$3.70 M
|
$577.00 K
|
$491.00 K
|
$216.00 K
|
$514.00 K
|
$1.15 M
|
$1.40 M
|
$1.72 M
|
$939.00 K
|
$1.72 M
|
| Depreciation & Amortization |
$492.00 K
|
$210.00 K
|
$178.00 K
|
$32.00 K
|
$3.14 K
|
$9.00 K
|
$9.00 K
|
$11.00 K
|
$27.00 K
|
$29.00 K
|
| EBITDA |
-$46.86 M |
-$48.41 M |
-$114.09 M |
-$18.77 M |
-$22.81 M |
-$25.45 M |
-$34.05 M |
-$36.29 M |
-$35.71 M |
-$41.25 M |
| EBITDA Ratio |
0
|
0
|
0
|
-156.41
|
-11
|
-107.39
|
-50.9
|
-14.31
|
-11.67
|
-7.19
|
| Operating Income Ratio |
0
|
0
|
0
|
-156.79
|
-11.23
|
-108.48
|
-51.45
|
-14.38
|
-12.84
|
-7.2
|
| Total Other Income/Expenses Net |
-$365.00 K
|
$1.39 M
|
-$75.46 M
|
-$202.00 K
|
-$42.00 K
|
-$905.00 K
|
-$1.04 M
|
-$1.56 M
|
$2.63 M
|
$2.04 M
|
| Income Before Tax |
-$51.06 M
|
-$49.20 M
|
-$114.76 M
|
-$19.02 M
|
-$23.33 M
|
-$26.62 M
|
-$35.46 M
|
-$38.02 M
|
-$36.68 M
|
-$43.00 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-158.48
|
-11.25
|
-112.3
|
-53
|
-14.99
|
-11.98
|
-7.5
|
| Income Tax Expense |
$0.00
|
$577.00 K
|
$88.30 M
|
$182.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.72 M
|
| Net Income |
-$51.06 M
|
-$49.77 M
|
-$203.06 M
|
-$19.20 M
|
-$23.33 M
|
-$26.62 M
|
-$35.46 M
|
-$38.02 M
|
-$36.68 M
|
-$44.72 M
|
| Net Income Ratio |
0
|
0
|
0
|
-159.99
|
-11.25
|
-112.3
|
-53
|
-14.99
|
-11.98
|
-7.8
|
| EPS |
-1.32 |
-1.32 |
-6.37 |
-0.52 |
-0.97 |
-26.18 |
-50.62 |
-18.86 |
-26.94 |
-44.68 |
| EPS Diluted |
-1.32 |
-1.32 |
-6.37 |
-0.52 |
-0.97 |
-26.18 |
-50.62 |
-18.86 |
-26.94 |
-43.62 |
| Weighted Average Shares Out |
$38.62 M
|
$37.79 M
|
$31.87 M
|
$37.11 M
|
$24.06 M
|
$1.02 M
|
$700.46 K
|
$2.02 M
|
$1.36 M
|
$1.00 M
|
| Weighted Average Shares Out Diluted |
$38.62 M
|
$37.79 M
|
$31.87 M
|
$37.11 M
|
$24.06 M
|
$1.02 M
|
$700.46 K
|
$2.02 M
|
$1.36 M
|
$1.03 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
